The soft tissue allograft market refers to the market for medical devices made from human tissues that are used to repair or replace damaged soft tissues in the body, such as tendons, ligaments, and cartilage. Soft tissue allografts are derived from donor tissues that are carefully screened and processed to ensure safety and efficacy. These allografts offer several advantages over synthetic materials, including better biocompatibility, lower risk of infection, and reduced inflammation.
The market for soft tissue allografts in 2021 was USD 12.93 billion, and by 2030 it will be worth USD 19.58 billion, growing at a 4.72% CAGR during the forecast period.
The global soft tissue allograft market is driven by the increasing incidence of sports injuries and orthopedic conditions, growing demand for minimally invasive procedures, and technological advancements in tissue processing and preservation.
Market Dynamics
Drivers
The market is expanding significantly as a result of the increased demand for soft tissue allografts in athletics and other sports. Athletes are required to participate in rigorous training sessions that, in reality, are more demanding than the actual sport to complete modern training regimens for athletics, field events, and a variety of other contact sports like American football. Athletes now demand speedy recovery and readily available modalities to treat musculoskeletal problems due to the competitive nature of sports.
The rising rate of osteoarthritis is also influencing the market growth of soft tissue allografts. According to figures from the United Kingdom National Health Service from 2020, tennis elbow was a frequent ailment affecting 3% to 4% of the population, or 4 to 7 instances per 1,000 people per year.
Restraints
Unintentional injuries have high financial repercussions. The annual cost to society and employers is in the billions of dollars. The National Safety Council estimates that the overall economic cost of nonfatal and fatal injury-related incidents that could have been prevented in 2020 was $1,158.4 billion, including expenses linked to motor vehicle crashes (39%), home injuries (33%), work injuries (14%), and public injuries (14%).
Opportunity
Controlling blood loss and achieving efficient hemostasis and wound closure in injuries, trauma, or surgical operations are urgent needs. According to data from the Consumer Product Safety Commission, injuries in sports and recreation were nearly 2.7 million in 2020ion. Most injuries occur in contact and collision-based sports, including racing, exercise, basketball, football, and soccer.
Market Segmentation
By Type
The collagen allograft segment was the largest market contributor with a significant revenue share. It is mainly because vascular and orthopedic surgeons mostly use these tools to treat diabetic foot ulcers, carry out ACL procedures, and perform other cosmetic surgeries.
By Application
The orthopedic segment held the largest position in the market. It is due to the expanding geriatric population, rising life expectancy, growing preference towards minimally invasive surgery, and increasing cases of bone disorders.
The dental segment will expand rapidly during the forecast period because more people are getting dental treatment. Furthermore, the market for soft tissue allografts is expanding because of increased rates of oral cancer, tooth decay, and population aging.
By End-User
Due to the worldwide growth in surgeries, the growing older population, and the increasing frequency of various diseases, the hospital segment held the largest market share. According to the National Safety Council’s injury data (2020), over twice as many males (3.44 million) as females (1.83 million) were wounded in the United States, and 91% of all 5.27 million injury victims were treated in hospital emergency rooms and released.
Regional Analysis
North America held a significant position in the market with the biggest revenue share in the regional market due to its developed healthcare system and a higher adoption rate of highly sophisticated goods and technology.
Asia Pacific is the fastest-growing industry for soft tissue allografts. Factors like the establishment of distribution channels by major businesses and the demand for collagen allografts to treat severe burn injuries and breast reconstruction procedures are stimulating growth in this region. According to research by The American Association of Tissue Banks (AATB), 58,000 tissue donors provide 3.3 million allografts.
Key Players
- Alon Source
- Zimmer Biomet
- MiMedix Group
- Lattice Biologics Ltd.
- AlloSource
- Conmed Corporation
- Osiris Therapeutics
- Organogenesis, Inc.
- Globus Medical, Inc.
- Integra Life Sciences Corporation
- Arthrex
- Bard, Inc. (Davol, Inc.)Braun Melsungen AG
- RTI Surgical, Inc.
- Straumann Holding AG
- Alliqua BioMedical, Inc.
- Xtant Medical
The market for soft tissue allografts in 2021 was USD 12.93 billion, and by 2030 it will be worth USD 19.58 billion, growing at a 4.72% CAGR during the forecast period. The rising frequency of anterior cruciate ligament sprains and tears is significantly stimulating the growth of the soft tissue allografts market.
Related Reports:
Automotive Sensor Market Report – The global automotive sensor market will witness a robust CAGR of 13.6%, valued at $23.3 Billion in 2021, and expected to appreciate and reach $26.46 Billion in 2022 and $74.42 Billion by 2030, confirms Strategic Market Research.